Abstract
Stroke is the third most common cause of death worldwide following ischemic heart disease and cancer and the number one condition associated with permanent disability. In Western countries, the yearly incidence of stroke is ∼ 0.2% of the population and the number of stroke-related death is expected to double over the next 30 years. Studies from the Netherlands and Scotland showed that stroke accounted for 3% to 5% of their total health care resources. For 2006, the estimated direct and indirect cost of stroke in the United States was ∼ 60 billion. Significant stenosis of the internal carotid artery is responsible for 10% to 20% of all strokes or transient ischemic attacks. Large-scale randomized clinical trials have established the superiority of carotid endarterectomy (CEA) over medical management in patients with high-grade stenosis of the internal carotid artery, particularly among symptomatic patients. Although percutaneous carotid revascularization has been performed since the early eighties, the enthusiasm has long been tempered by the fear of cerebral embolism. Following the introduction of emboli protection devices (EPD) around the year 2000, the number of procedures performed worldwide has grown exponentially. We review the available studies on carotid stenting and discuss appropriate use of this procedure. Emphasis is also placed on optimal long-term pharmacotherapy in patients with carotid stenosis.
Keywords: Carotid stenosis, carotid endarterectomy, carotid stenting, secondary prevention
Current Vascular Pharmacology
Title: Current Status of Carotid Stenting
Volume: 6 Issue: 2
Author(s): Ji Sun Kim and Debabrata Mukherjee
Affiliation:
Keywords: Carotid stenosis, carotid endarterectomy, carotid stenting, secondary prevention
Abstract: Stroke is the third most common cause of death worldwide following ischemic heart disease and cancer and the number one condition associated with permanent disability. In Western countries, the yearly incidence of stroke is ∼ 0.2% of the population and the number of stroke-related death is expected to double over the next 30 years. Studies from the Netherlands and Scotland showed that stroke accounted for 3% to 5% of their total health care resources. For 2006, the estimated direct and indirect cost of stroke in the United States was ∼ 60 billion. Significant stenosis of the internal carotid artery is responsible for 10% to 20% of all strokes or transient ischemic attacks. Large-scale randomized clinical trials have established the superiority of carotid endarterectomy (CEA) over medical management in patients with high-grade stenosis of the internal carotid artery, particularly among symptomatic patients. Although percutaneous carotid revascularization has been performed since the early eighties, the enthusiasm has long been tempered by the fear of cerebral embolism. Following the introduction of emboli protection devices (EPD) around the year 2000, the number of procedures performed worldwide has grown exponentially. We review the available studies on carotid stenting and discuss appropriate use of this procedure. Emphasis is also placed on optimal long-term pharmacotherapy in patients with carotid stenosis.
Export Options
About this article
Cite this article as:
Kim Sun Ji and Mukherjee Debabrata, Current Status of Carotid Stenting, Current Vascular Pharmacology 2008; 6 (2) . https://dx.doi.org/10.2174/157016108783955347
DOI https://dx.doi.org/10.2174/157016108783955347 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteomic Profiling of Maternal Serum for Early Risk Analysis of
Preterm Birth
Current Proteomics Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Current Drug Safety Female Infertility and Cardiovascular Risk - A Hype or an Underestimated Reality?
Current Pharmaceutical Design Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?
Current Vascular Pharmacology Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Non-invasive Atherosclerosis Imaging: Use to Assess Response to Novel or Combination Lipid Therapies
Current Drug Targets - Cardiovascular & Hematological Disorders Intestinal Fatty acid Absorption
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pharmacological Targeting in Inherited Arrhythmia Syndromes
Current Medicinal Chemistry Biomarkers of Alcohol Consumption in Body Fluids - Possibilities and Limitations of Application in Toxicological Analysis
Current Medicinal Chemistry Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry 1,8-Naphthyridine Derivatives: A Privileged Scaffold for Versatile Biological Activities
Mini-Reviews in Medicinal Chemistry Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Capacity Building in Genomics Medicine and Molecular Diagnostics: The Case of Sri Lanka
Current Pharmacogenomics and Personalized Medicine Sex Differences in Clinical Outcomes of Patients with Stable Coronary Artery Disease after Percutaneous Coronary Intervention
Current Pharmaceutical Design Casein Phosphopeptides in Oral Health - Chemistry and Clinical Applications
Current Pharmaceutical Design N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain
Current Pharmaceutical Design Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology Editorial (Thematic Issue: Novel Insights into the Role of Anesthetics and Opioids in Organ or Tissue Protection)
Current Pharmaceutical Design The Antidiabetic Effects of The Bioactive Flavonoid (Kaempferol-3-O-β-D-6{P- Coumaroyl} Glucopyranoside) Isolated From Allium cepa
Recent Patents on Anti-Infective Drug Discovery Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
Current Vascular Pharmacology